한국MSD MSD Korea
한국MSD (MSD Korea) is the Seoul-based Korean subsidiary of Merck & Co., Inc., developing, registering, and commercializing innovative prescription medicines and vaccines across vaccines, oncology, and hospital specialty therapeutic areas to Korean healthcare providers and patients.
- Company typePrivate
- Founded-
- HeadquartersSeoul, South Korea
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What 한국MSD MSD Korea does
한국MSD (MSD Korea), formally 한국엠에스디(주), is the Korean subsidiary of Merck & Co., Inc. (NYSE: MRK), headquartered in Rahway, New Jersey, USA, and operates as a wholly-owned entity from its Seoul office. The company is a research-focused biopharmaceutical enterprise that develops, registers, and commercializes innovative prescription medicines and vaccines in Korea. Its therapeutic portfolio is organized around three pillars: Vaccines (including Gardasil HPV vaccines, shingles, MMR, rotavirus, pneumococcal, and Capvaxive); Oncology (anchored by Keytruda/pembrolizumab in both IV and the newly approved subcutaneous form, alongside Welireg, Temodal, and Oncotype DX); and Hospital Specialty (spanning HIV treatments such as Isentress and Pifeltro, anti-infectives including Prevymis for CMV, antibiotics like Invanz and Zerbaxa, and neurology products such as Bridion and Esméron).
The company's go-to-market is an enterprise field-sales model targeting hospitals, clinics, and healthcare professionals through direct sales interactions, clinical trial engagement, and medical information sharing. Distribution occurs through healthcare institutions and licensed pharmacies, with Zuellig Pharma Korea serving as the primary logistics and cold-chain distribution partner. Revenue is generated primarily through prescription product sales reimbursed under Korea's national health insurance system, with pricing regulated by government authorities and not publicly disclosed at the Korea-subsidiary level. The company also invests heavily in localized clinical research, running 180 active trials with domestic research institutions as of April 2025 and ranking #1 among Korean pharmaceutical companies for MFDS clinical trial approvals in 2024 (36 new approvals), with 720 billion KRW in domestic R&D investment. Technology infrastructure relies on enterprise partners (Salesforce, Oracle, Veeva, Microsoft, Workday, SAP) for CRM, clinical data management, and ERP functions.
한국MSD MSD Korea firmographics
Firmographics- Name
- 한국MSD MSD Korea
- Legal name
- Merck & Co., Inc.
- Website
- https://msd-korea.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- 한국MSD (MSD Korea) is the Seoul-based Korean subsidiary of Merck & Co., Inc., developing, registering, and commercializing innovative prescription medicines and vaccines across vaccines, oncology, and hospital specialty therapeutic areas to Korean healthcare providers and patients.
- Ownership category
- akta.pro rank
한국MSD MSD Korea industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)
- akta.pro secondary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where 한국MSD MSD Korea is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
한국MSD MSD Korea business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Pharmaceutical Products: Sales of prescription medicines and vaccines to healthcare providers, hospitals, and through pharmacies. Revenue is generated through product sales across therapeutic areas including vaccines, oncology, and hospital specialty products.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
한국MSD MSD Korea product offering
Product offeringCore offering
한국MSD (MSD Korea) is the Korean subsidiary of Merck & Co., Inc. and a research-focused biopharmaceutical company that develops and supplies innovative prescription medicines and vaccines. Its portfolio is organized into three therapeutic areas: Vaccines (HPV, rotavirus, hepatitis A, MMR, varicella, pneumococcal), Oncology (immuno-oncology and targeted therapies), and Hospital Specialty (anti-infectives, HIV, CMV, surgical, and supportive care products). The company sells products through hospitals, clinics, and pharmacies in Korea and conducts clinical trials with domestic research institutions.
Product overview
한국MSD는 MSD(Merck Sharp & Dohme)의 한국 법인으로, 혁신적인 의약품과 백 신을 개발 및 공급하는 연구 중심 바이오제약 기업입니다. 핵심 영역으로는 3가지를 제시합니다: (1)백신(Vaccines) - 가다실®, 가다실9®, 박타®, 엠엠알II, 로타텍®, 바리박스®, 박스뉴반스®, 프로디악스®, 캡박시브 등 HPV, A형간염, MMR, 로타바이러스, 수두, 폐렴구균 예방백신 포트폴리오, (2)항암제(Oncology) - 키트루다®(펨브롤리주맙), 테모달®, 온코타이스® 등 면역항암제 및 항암제, (3)호스피탈 스페셜티(Hospital Specialty) - 녹사필®, 칸시다스®, 인반즈®, 이센트레스®, 프레비미스®, 윈레브에어®, 저박사®, 에멘드®, 브리디온®, 에스메론®, 피펠트로정, 델스트리고®, 웰리렉®, 엔플론시아 등 감염병, HIV, CMV, 신경근육차단제 회복, 구역제 등 병원 내 치료 영역 전반의 제품.
Differentiator
Problem solved
Functional benefit
Brands
- MSD: Global research-focused biopharmaceutical company brand under which 한국MSD operates, developing and supplying innovative medicines and vaccines.
Products and services
- 가다실® (Gardasil®) HPV 4-valent vaccine (가다실주 / Gardasil Injection) Recombinant HPV 4-valent vaccine administered as an intramuscular injection for prevention of diseases caused by HPV types 6, 11, 16, and 18, including cervical cancer and genital warts. Sold to healthcare providers and prescribed to patients in Korea.
- 가다실9® (Gardasil 9®) HPV 9-valent vaccine
Companies that use 한국MSD MSD Korea
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
한국MSD MSD Korea technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
한국MSD MSD Korea partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and supporting.
- Merck & Co., Inc., Rahway, NJ, USA and affiliatescoreParent company and global headquarters providing strategic direction, R&D investment ($17.9B in 2024), and global operational support. MSD Korea operates as a subsidiary implementing global pharmaceutical development and commercialization strategies in Korea.
- Domestic Research InstitutionscoreCollaboration with 180 domestic research institutions conducting clinical trials in Korea as of April 2025. This includes universities, hospitals, and research centers participating in clinical research programs.
- Clinical Trial Partners (ICON, Syneos, Parexel, Fortrea, LabCorp, and others)coreExtensive network of global clinical research organizations supporting clinical trial execution, data management, laboratory analysis, and regulatory submissions. Includes central labs, imaging, patient-reported outcomes, and eCRF systems.
- Salesforce, Oracle, Veeva Systems, MicrosoftcoreTechnology partners for customer relationship management, clinical data management, cloud infrastructure, and enterprise software supporting pharmaceutical operations and compliance.
- Workday, SAPsupportingHR and enterprise resource planning systems for employee management, payroll, and financial operations.
- Seoul National University Industry-Academia CollaborationsupportingCollaboration with Seoul National University School of Medicine's Health and Environment Research Institute for sexual health education programs and research activities.
- Zuellig Pharma KoreacorePrimary pharmaceutical logistics and distribution partner handling product distribution, cold chain management, and adverse event/product quality complaint reporting.
Scale indicators7 records
Recent moves6 records
Expansion highlights4 records
한국MSD MSD Korea competitors and assessment
Company assessmentDirect peers
- Johnson & Johnson Innovative Medicine Korea: J&J Korea is the Korean subsidiary of Johnson & Johnson, a direct peer in oncology, hospital specialty, and infectious diseases, with a comparable multinational pharma GTM motion targeting Korean hospitals and clinical research sites.
- Bayer Korea: Bayer Korea is the Korean subsidiary of Bayer AG, a direct peer in specialty pharmaceuticals, women's health, and radiology with comparable multinational GTM into Korean hospitals and healthcare providers.
- AbbVie Korea: AbbVie Korea is the Korean subsidiary of AbbVie Inc., a direct peer in specialty pharmaceuticals, oncology, and immunology with similar hospital-focused commercialization and clinical research presence in Korea.
- AstraZeneca Korea: AstraZeneca Korea is the Korean subsidiary of AstraZeneca plc, a direct peer in oncology (competing IO and targeted therapy franchises), specialty pharmaceuticals, and respiratory, with growing clinical trial presence in Korea.
- Eli Lilly Korea: Eli Lilly Korea is the Korean subsidiary of Eli Lilly and Company, a direct peer in oncology, specialty pharmaceuticals, and diabetes, with overlapping Korean hospital channel focus and clinical trial infrastructure.
- Sanofi Korea: Sanofi Korea is the Korean subsidiary of Sanofi S.A., a direct peer in vaccines (including competing pediatric and adult vaccines), specialty pharmaceuticals, and rare diseases, with similar distribution and clinical research operations in Korea.
- GSK Korea: GSK Korea is the Korean subsidiary of GSK plc, a direct peer in vaccines (including HPV and pneumococcal competing products), specialty pharmaceuticals, and HIV, sharing similar regulatory and hospital channel dynamics.
- Novartis Korea: Novartis Korea is the Korean subsidiary of Novartis AG, a direct peer in oncology, specialty pharmaceuticals, and innovative medicines with comparable GTM motion targeting Korean hospitals and healthcare providers.
- Roche Korea: Roche Korea is the Korean subsidiary of F. Hoffmann-La Roche AG, a direct peer in oncology (competing with Keytruda), diagnostics, and specialty pharmaceuticals, with a similar hospital channel focus and clinical trial footprint in Korea.
- Pfizer Korea: Pfizer Korea is the Korean subsidiary of Pfizer Inc., a direct peer in vaccines (including pneumococcal and HPV competing products), oncology, and hospital specialty pharmaceuticals operating in the same Korean market with similar GTM motion and customer base.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
한국MSD MSD Korea social profiles
Digital presence한국MSD MSD Korea financial estimates
Financial estimateRevenue estimate
Valuation estimate
한국MSD MSD Korea leadership team
Management profileNumber of profiles
Profiles1 record
한국MSD MSD Korea funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
한국MSD MSD Korea M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 한국MSD MSD Korea
What does 한국MSD MSD Korea do?
한국MSD (MSD Korea) is the Korean subsidiary of Merck & Co., Inc. and a research-focused biopharmaceutical company that develops and supplies innovative prescription medicines and vaccines. Its portfolio is organized into three therapeutic areas: Vaccines (HPV, rotavirus, hepatitis A, MMR, varicella, pneumococcal), Oncology (immuno-oncology and targeted therapies), and Hospital Specialty (anti-infectives, HIV, CMV, surgical, and supportive care products). The company sells products through hospitals, clinics, and pharmacies in Korea and conducts clinical trials with domestic research institutions.
Is 한국MSD MSD Korea a public or private company?
한국MSD MSD Korea is a private company. It is classified as corporate owned and is currently operating.
When was 한국MSD MSD Korea founded?
한국MSD MSD Korea was founded in -1. It employs 101 to 250 people.
Where is 한국MSD MSD Korea based?
한국MSD MSD Korea is headquartered in Seoul, South Korea, in the Asia region.
How does 한국MSD MSD Korea make money?
One revenue line is on record: pharmaceutical Products.
Who are 한국MSD MSD Korea's main competitors?
Direct peers on record are Johnson & Johnson Innovative Medicine Korea, Bayer Korea, AbbVie Korea, AstraZeneca Korea, Eli Lilly Korea, Sanofi Korea, GSK Korea, Novartis Korea, Roche Korea and Pfizer Korea.
Does 한국MSD MSD Korea have an API?
No public API is recorded for 한국MSD MSD Korea.
What industry is 한국MSD MSD Korea in?
한국MSD MSD Korea's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAEAN, Vaccine Procurement, Tendering & Immunization Supply Programs, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.